HIM
APLS

Hillsdale Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History

Hillsdale Investment Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,600
Closed -$652K – 561
2022
Q4 		$652K Hold
12,600
– – 0.06% 266
2022
Q3 		$861K Buy
+12,600
New +$746K 0.08% 178

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hillsdale Investment Management's APLS Position: Q1 2023 in Review

Hillsdale Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2023, closing a stake of 12,600 shares — an estimated $652K sold.

Hillsdale Investment Management first reported a position in APLS in Q3 2022 and held it in 2 quarters. The position peaked at $861K in Q3 2022. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

  • Hillsdale Investment Management reported no remaining Apellis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Hillsdale Investment Management sold 12,600 Apellis Pharmaceuticals shares in Q1 2023, an estimated $652K.
  • Hillsdale Investment Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Hillsdale Investment Management's Apellis Pharmaceuticals position peaked at $861K in Q3 2022.
  • 281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on Hillsdale Investment Management's 13F filing for Q1 2023, filed 10 May 2023.